Daiichi Sankyo (TYO: 4568), a leading Japanese pharmaceutical company, has announced the official market launch of its medication Tarlige (mirogabalin) in China, targeting the treatment of diabetes peripheral neuropathic pain (DPNP). This third-generation calcium channel regulator received marketing approval in China in July of this year and holds the potential to be included in the National Reimbursement Drug List (NRDL) adjustments, which are anticipated to take place later this year.
The introduction of Tarlige to the Chinese market marks a significant advancement in the therapeutic options available for patients suffering from DPNP. With its anticipated inclusion in the NRDL, access to this novel treatment is likely to be broadened, offering both patients and healthcare providers an additional choice for managing this chronic condition.- Flcube.com
